Trial News & Events

Ezogabine treatment shown to reduce motor neuron excitability in ALS patients

Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital (MGH) presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland.

NEALS Meeting at the MND Symposium

Please join us for a presentation on plans for an ALS Platform Trial through the NEALS Consortium. The NEALS satellite meeting will be held on Sunday, December 9th from 7:15 – 8:15 AM.

NEALS Satellite Meeting at AAN 2018

There will be a NEALS Consortium satellite meeting at the 70th AAN Annual Meeting on Wednesday, April 25, 2018.

Updates from the NEALS Subcommittees

NEALS has established various subcommittees focused on advancing ALS research and patient care. In an effort to keep our members and subscribers informed about what these focus groups are working on, NEALS will distribute a semi-annual update on committee activities.

Call for Nominations: Arizona Clinical Research Learning Institute

The CRLI is a two-day program dedicated to educating attendees on clinical research and therapy development and empowering this group to be even more effective research advocates. Local patients, caregivers, surviving spouses and family, and patient-caregiver pairs are encouraged to apply by May 15, 2018.

FORTITUDE-ALS Now Enrolling

FORTITUDE-ALS is a clinical trial of an investigational oral drug for the treatment of amyotrophic lateral sclerosis (ALS). This clinical trial is now enrolling participants in both the United States and Canada.